Paul Firuta | Chief Commercial Officer

Paul Firuta, Chief Commercial Officer, uniQure

Mr. Firuta joins uniQure from BioBlast Pharma (NASDAQ: ORPN) where he held the position of Chief Commercial Officer. Prior to this, he was President of U.S. Commercial Operations at NPS Pharmaceuticals were he lead the development and execution of the GATTEX sales and marketing plan as well as the commercial launch of NAPTARA. Over the course of his career, Mr. Firuta has held various leadership roles at biopharmaceutical companies including Vice President and General Manager, Americas at ViroPharma, Inc. where he was responsible for U.S. commercial operations for CINRYZE and VANCOCIN, representing over $400 million in U.S. revenue. Additionally, he was Vice President – Managed Markets at LEV Pharmaceuticals and Executive Director National Accounts at OraPharma. Mr. Firuta holds a Master of Business Administration from St. Joseph's University in Philadelphia, Pennsylvania and a Bachelor of Science degree from King's College, Wilkes-Barre, Pennsylvania.


Advanced Therapies and Regenerative Medicine Day 1 - Wednesday 16th May 2018 @ 14:50

Panel discussion: Pricing, reimbursement, and market access for cell & gene therapies: challenges and potential solutions

  • Pricing and reimbursement to-date of pioneering cell and gene therapies in the EU and US
  • Challenges and approaches to defining and demonstrating therapy value, including perspectives on NICE & ICER reviews
  • The range of reimbursement models likely to emerge (multi-year, outcomes-based, other value-based arrangements, etc.)
  • How partners and intermediaries might fit into and shape future value chains

back to speakers



Erica Baeta
+44 (0)207 092 1152


Jessica Robinson
t/ +44 (0)207 092 1150


Issa Mauthoor
+44 (0)207 092 1257